Ranbaxy Laboratories

From Wikipedia, the free encyclopedia

Ranbaxy Laboratories Limited
Type	Public
Founded	1961
Headquarters	Gurgaon, Haryana, India
Key people	Tejendra Khanna, Chairman Brian Tempest, Chief Mentor, Executive Vice Chairman Malvinder Mohan Singh, CEO & MD
Industry	Pharmaceutical
Products	Generic drugs
Revenue	$1.178 billion (2005)
Employees	1100 in R&D
Website	www.ranbaxy.com

Ranbaxy Laboratories Limited is an Indian company incorporated in 1961. It is India's largest pharmaceutical company. It exports its products to 125 countries with ground operations in 46 and manufacturing facilities in 7 countries. It is ranked among the top 10 generic companies worldwide. The CEO of the company is Malvinder Mohan Singh.

Ranbaxy went public in 1973.

In 1998, Ranbaxy entered the USA, the world's largest pharmaceuticals market and now the biggest market for Ranbaxy, accounting for 28% of Ranbaxy's sales in 2005.

For the twelve months ending on December 31, 2005, the Company's Global Sales were at US $1.178 billion with overseas markets accounting for 75% of global sales(USA: 28%, Europe: 17%, Brazil, Russia, India and China: 29%).

Most of Ranbaxy's products are manufactured by license from foreign pharmaceutical developers, though a significant percentage of their products are off-patent drugs that are manufactured and distributed without licensing from the original manufacturer because the patents on such drugs have expired.

In December 2005, Ranbaxy's shares were hit hard by a patent ruling disallowing production of its own version of Pfizer's cholesterol-cutting drug Lipitor, which has annual sales of more than $10 billion.BBC

On June 23, 2006, Ranbaxy received from the U.S. Food & Drug Administration a 180-day exclusivity period to sell simvastatin (Zocor) in the U.S. as a generic drug at 80 mg strength. Ranbaxy presently competes with the maker of brand-name Zocor, Merck & Co.; Teva Pharmaceutical Industries, which has 180-day exclusivity at strengths other than 80 mg; and Dr. Reddy's Laboratories, also from India, whose authorized generic version (licensed by Merck) is exempt from exclusivity.

The emergence of at least one "Chinese Ranbaxy" over the next few years could catalyse consolidation in the generics segment in India and abroad, says Rajiv Shukla, vice-president of business development and marketing at Advinus Therapeutics. Speaking at IBC's 3rd annual international conference on pharma R&D partnering and innovation India, in Mumbai, Mr Shukla said that such a firm could be helped along by the Chinese government and provoke a pause for thought in and outside India. Ranbaxy is India's largest pharmaceutical company and a key player in the global generics market. Alluding to the formation of a similar business in China Mr Shukla told Scrip, "It will possibly be constructed by the Chinese government [Chinese firms facing consolidation could be combined] and would then go public." Indian firms are also expected to become active on both the buy and sell side of mergers and acquisitions. Mr Shukla expects international generics companies to make at least one $1 billion acquisition in India, with mid-market acquisitions remaining "lively". Mylan Laboratories recently acquired India's Matrix Laboratories for about $736 million in the largest ever acquisition in the Indian pharmaceutical industry. On the other hand, Indian generics companies, backed by increased confidence from their recent M&A experiences, are also expected to start making acquisition bids in the $1 billion range, and could acquire overseas R&D, Mr Shukla added. During the first quarter of this year, Indian pharma companies spent close to $1 billion in acquiring European assets, says a report by the Indian investment banking firm Mape Advisory.

[edit] External links

• Ranbaxy: Official site

·